Provided by: Chunghwa Chemical Synthesis & Biotech Co.,Ltd
SEQ_NO
1
Date of announcement
2022/08/09
Time of announcement
16:54:02
Subject
Announce the company's 2022Q2 consolidated financial
reports approved by the board of directors.
Date of events
2022/08/09
To which item it meets
paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
directors:2022/08/09
2.Date of approval by the audit committee:2022/08/09
3.Start and end dates of financial reports or annual self-assessed financial
information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):1,108,934
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):530,098
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):292,251
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):362,831
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):275,721
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):275,556
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):3.55
11.Total assets end of the period (thousand NTD):4,401,515
12.Total liabilities end of the period
(thousand NTD):1,411,351
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,989,790
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chunghwa Chemical Synthesis & Biotech Co. Ltd. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 11:05:04 UTC.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
